BPC June 17 updates: ARIA initiates rolling NDA. KURA added to database + SMMT EARS MDGN updates

Jun 18, 2016 No Comments by

Updates to the Company Pipeline Database for June 17, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary EARS 4.14 AM-111 HEALOS/ASSENT Acute inner ear hearing loss Phase 3 Commenced HEALOS (EU) trial in November 2015.ASSENT trial (US) commenced June 2016. HEALOS data due 2H 2017 MDGN 5.98 NFC-1 – SAGA […]

Daily News Read more

BPC June 13 updates: KMPH issued CRL. MRNS and RVNC both fail Phase 3 trials + updates for ARGS ARIA FCSC MESO ONCE VICL

Jun 14, 2016 No Comments by

Updates to the Company Pipeline Database for June 13, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARGS 5.95 AGS-003 ADAPT Trial Metastatic renal cell carcinoma (mRCC) Phase 3 Third interim analysis June 2016. Overall survival analysis due 1H 2017 ARIA 8.20 Iclusig (ponatinib) – OPTIC-2L Cancer – second line […]

Daily News Read more

BPC May 18 updates – ARIA and DNAI Phase 2 data due at ASCO + updates for AFMD ARRY IMGN ORMP

May 18, 2016 No Comments by

Updates to the Company Pipeline Database for May 18, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AFMD 3.10 AFM13 Hodgkin Lymphoma Phase 2 Phase 2a enrolment has slowed. Company to provide timeline update once enrolment trend is established ARIA 7.85 Brigatinib – ALTA trial Anaplastic lymphoma kinase positive (ALK+) […]

Daily News Read more

Pipeline updates from reporting companies – ARIA AVEO BCLI BDSI BLPH BSTC BTX CCXI CERU CYTX DERM FOMX GALE GTXI IMDZ MDGN OCUL OMER PBYI STEM TGTX TKAI VICL VKTX VTAE XENE ZIOP

May 11, 2016 No Comments

Updates to the Company Pipeline Database for May 10, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARIA 7.64 AP32788 Cancer – non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 enrolling as of May 2016 ARIA 7.64 Brigatinib – ALTA trial Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell […]

Read more

ARIA initiates Phase 3 Brigatinib trial. VKTX and BOTA updates. CRTV added to database.

Apr 11, 2016 No Comments

Updates to the Company Pipeline Database for April 11, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARIA 6.34 Brigatinib ALK+ non-small cell lung cancer (NSCLC) – front line Phase 3 Phase 3 trial initiated April 2016. Enrolment to be completed 2018 BOTA 1.59 BTA585 Respiratory syncytial virus (RSV) […]

Read more

PTCT receives Refusal to File Letter. CLDX Phase 3 data due March + updates for ALDR AMAG ARIA BCRX ICPT INFI NVIV PRTK PTCT

Feb 24, 2016 No Comments

Updates to the Company Pipeline Database for February 23, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDR 19.29 ALD403 Chronic Migraine Phase 2b Phase 2b data due 1Q 2016 ALDR 19.29 ALD403 – PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 topline data due 1H 2017 AMAG […]

Read more

ALNY completes Phase 3 APOLLO enrollment + updates for ARIA CBYL DSCO REPH TENX TTHI

Feb 02, 2016 No Comments

Updates to the Company Pipeline Database for February 1, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALNY 69.75 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 enrolment completed late January 2016. Data due 2017, with NDA to be filed late 2017 assuming […]

Read more

61 pipeline updates for 42 companies from May 7 and 8

May 09, 2015 1 Comment

Latest updates to the Company Pipeline Database for May 7 and 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACHN 9.43 ACH-3422 in combination with ACH-3102 HCV Hepatitis C – treatment durations of 6, 8 and 12 weeks Phase 2 Phase 2 to be initiated 2Q 2015. SVR4 results are expected […]

Read more

Updates for week ending February 20

Feb 20, 2015 No Comments

Latest updates to the Company Pipeline Database for week ending February 20, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AGIO 106.30 AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 trial to be initiated 1H 2015 2/21/2015 ARIA 8.06 Brigatinib – ALTA trial Anaplastic lymphoma kinase […]

Read more

Latest pipeline updates. 40 in total!

Jan 13, 2015 No Comments

Latest updates to the Company Pipeline Database from January 12 and 13, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ATRS 2.46 VIBEX QuickShot Testosterone deficiency Phase 3 Phase 3 initiated July 2014. Final patient dosed Nov 2015. Top-line pharmacokinetic data due 2Q 2015 1/14/2015 CPRX 2.87 […]

Read more

KBIO Phase 2 trial failure. CNAT data due this week + updates for ARIA CANF RARE TNXP TRVN AKBA BCLI CEMP CYTR MSTX RVNC RLYP GEVA

Jan 07, 2015 No Comments

Latest updates to the Company Pipeline Database from January 5 and 6, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ARIA 6.51 Iclusig (ponatinib) Cancer – refractory chronic-phase chronic myeloid leukemia (CP-CML) Phase 2 Phase 2 dose ranging trial to be initiated mid 2015 1/7/2015 CANF […]

Read more